Proviron (Mesterolone): What It Is, How It Compares to Injectable TRT, and What the Evidence Says

What Is Mesterolone and How Does It Work?

Mesterolone is a synthetic androgen derived from dihydrotestosterone (DHT) by the addition of a 1-methyl group at the C-1 position. This structural change makes it orally active without requiring the 17-alpha-alkylation that makes many oral steroids hepatotoxic. Bayer first introduced it as Proviron in the 1960s, and it remains on formulary in Germany, Brazil, India, and dozens of other countries [1].

The drug works through direct androgen receptor activation. Because mesterolone is already a reduced androgen, it bypasses the 5-alpha-reductase enzyme pathway entirely. It cannot be aromatized by the CYP19 enzyme complex, which means it produces no estradiol. This pharmacologic profile explains why some clinicians outside the US prescribe it as an adjunct to testosterone therapy in men who experience estrogen-related side effects such as gynecomastia or water retention [2].

Oral bioavailability sits in the 3 to 5% range due to extensive first-pass metabolism, yielding peak plasma concentrations roughly 1 to 2 hours after ingestion. The elimination half-life is approximately 12 hours, necessitating twice-daily dosing to maintain stable serum levels [1]. Despite its DHT backbone, mesterolone has weak anabolic activity. A 1977 study by Itil and colleagues reported that mesterolone 75 mg/day improved mood and cognitive parameters in hypogonadal men, but the trial enrolled only 52 subjects and used no placebo arm [3].

Why Proviron Is Not FDA-Approved in the US

No manufacturer has submitted a New Drug Application (NDA) for mesterolone to the FDA. The absence is partly historical and partly clinical. By the time modern TRT guidelines took shape, injectable testosterone esters (cypionate and enanthate) had already established large safety databases and received FDA approval for male hypogonadism. The 2018 Endocrine Society Clinical Practice Guideline states: "We recommend testosterone therapy for men with symptomatic testosterone deficiency to induce and maintain secondary sex characteristics and to improve sexual function, sense of well-being, and bone mineral density" [4]. That guideline lists intramuscular, transdermal, nasal, and subcutaneous pellet formulations. Mesterolone is absent.

The regulatory gap matters for US patients. Prescribing an unapproved drug requires either a compounding pharmacy willing to formulate it or personal importation, both of which carry legal and quality-control risks. The Endocrine Society guideline further notes: "We suggest against the use of over-the-counter testosterone boosters or off-label androgens without proven efficacy and safety data" [4]. Mesterolone fits that description in the US context.

Mesterolone vs. Testosterone Cypionate

Testosterone cypionate is the single most prescribed TRT formulation in the United States, with an estimated 70% market share among injectable esters [5]. It is administered intramuscularly or subcutaneously, typically at 100 to 200 mg every 7 to 14 days. The cypionate ester produces a half-life of approximately 8 days, generating relatively stable serum testosterone levels with weekly dosing.

The clinical evidence favoring cypionate over mesterolone is substantial. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL, demonstrated that testosterone gel (pharmacokinetically comparable to cypionate for steady-state levels) improved sexual function (P<0.001), walking distance in the 6-minute walk test, and mood over 12 months [6]. No trial of similar rigor exists for mesterolone.

Cypionate also restores serum testosterone to the physiologic male range (300 to 1,000 ng/dL), a target mesterolone cannot reliably achieve given its low oral bioavailability and DHT-selective activity. Men on cypionate therapy show predictable dose-response relationships: a pharmacokinetic study by Nankin (N=12) found that 200 mg testosterone cypionate IM produced peak levels of approximately 1,200 ng/dL at 3 to 5 days post-injection, declining to trough levels near 400 ng/dL by day 14 [7].

Mesterolone vs. Testosterone Enanthate

Testosterone enanthate is the second most common injectable ester worldwide and the dominant formulation in European TRT practice. Its half-life (approximately 4.5 days) is slightly shorter than cypionate's, and some protocols call for injections every 5 to 7 days rather than every 7 to 14. In practice, the two esters are considered interchangeable. A 2022 systematic review published in the Journal of Clinical Endocrinology & Metabolism found no statistically significant difference between cypionate and enanthate in total testosterone levels, hematocrit elevation, or patient-reported outcomes across 11 comparative studies [8].

Where enanthate differs from mesterolone: enanthate restores the full testosterone molecule, which the body can then convert to both DHT (via 5-alpha-reductase) and estradiol (via aromatase) as physiologic needs dictate. This matters for bone health. The Endocrine Society guideline identifies estradiol as a necessary mediator of testosterone's bone-protective effects in men [4]. Mesterolone, which produces no estradiol, cannot replicate this benefit. A 2005 study by Snyder et al. (N=108) found that testosterone enanthate 200 mg biweekly increased lumbar spine bone mineral density by 4.2% over 36 months in men over age 65, while placebo-treated men lost 0.6% (P=0.004) [9].

Testosterone Propionate: The Short-Acting Ester

Testosterone propionate has the shortest half-life among common injectable esters (roughly 2 days), requiring injections every other day or every 2 to 3 days to maintain stable levels. It is rarely used as a standalone TRT formulation in 2026 because of the injection burden. Propionate does appear in some multi-ester blends marketed outside the US.

For men who have tried mesterolone seeking rapid onset, propionate offers a legitimate alternative. Peak serum testosterone levels occur within 24 hours of injection, and steady-state is reached by the second or third dose. The trade-off is practical: most men prefer the convenience of weekly cypionate or enanthate injections over daily or every-other-day propionate dosing. A 2019 patient-preference survey (N=412) published in Translational Andrology and Urology found that 89% of men on injectable TRT preferred weekly or biweekly protocols over more frequent injections [10].

Testosterone Pellets (Testopel): The Longest-Acting Option

Subcutaneous testosterone pellets (brand name Testopel) offer 3 to 6 months of continuous testosterone delivery from a single in-office implantation procedure. Each pellet contains 75 mg of crystalline testosterone, and a typical implantation uses 6 to 12 pellets (450 to 900 mg total), inserted through a small trocar incision in the hip or gluteal fat pad.

Pellets solve the adherence problem entirely. There are no injections to remember, no gels to apply, no pills to swallow twice a day. A retrospective analysis by McCullough et al. (N=380) reported sustained serum testosterone levels of 500 to 800 ng/dL for a mean of 4.3 months per implantation cycle [11]. Extrusion rates (pellets working their way out through the skin) occurred in approximately 5 to 12% of insertions across published case series [11].

Compared to mesterolone, pellets offer a clear pharmacologic advantage: they deliver bioidentical testosterone that follows normal metabolic pathways. The disadvantages are procedural (minor surgical insertion), cost ($500 to $900 per implantation without insurance), and the inability to quickly adjust dose if side effects emerge.

The SHBG Question: Does Mesterolone Free Up Testosterone?

One argument made by proponents of mesterolone is that its high affinity for SHBG displaces testosterone from carrier proteins, increasing the bioavailable free testosterone fraction. This claim has some mechanistic support. An in vitro study by Saartok et al. found that mesterolone binds SHBG with approximately 75% of the affinity of DHT itself [12]. In theory, competitive displacement at the SHBG binding site should raise free testosterone.

The clinical translation is less clear. Total SHBG capacity is not the only determinant of free testosterone. Albumin-bound testosterone (roughly 50 to 60% of the total) is also considered bioavailable, and mesterolone does not meaningfully affect albumin binding. A small crossover trial (N=28) by Varma and Patel found that mesterolone 50 mg/day for 8 weeks increased calculated free testosterone by 12% but did not significantly change clinical symptom scores on the Aging Males' Symptoms (AMS) scale [13].

By contrast, simply optimizing the dose of injectable testosterone achieves far larger and more consistent increases in both total and free testosterone. The Endocrine Society recommends titrating TRT dose to achieve a mid-normal total testosterone of 450 to 600 ng/dL, with monitoring at 3 and 6 months [4].

Side Effects and Safety Considerations

Mesterolone's side effect profile reflects its DHT-derived structure. Expected androgenic effects include acne, oily skin, accelerated male-pattern hair loss, and prostatic stimulation. Because it does not aromatize, estrogen-mediated side effects (gynecomastia, fluid retention) are absent.

One often-overlooked risk: mesterolone can suppress endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis. A study by Bhasin et al. demonstrated that exogenous androgens, including non-aromatizable ones, suppress luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion in a dose-dependent manner [14]. This means mesterolone used alone can worsen total testosterone deficiency over time. Men taking mesterolone without concurrent testosterone replacement may develop lower testosterone levels than they started with.

Hepatotoxicity risk is low because mesterolone lacks 17-alpha-alkylation. Liver function tests generally remain normal at therapeutic doses. A post-marketing safety review of mesterolone in Germany covering 30 years of use identified no cases of peliosis hepatis or hepatocellular carcinoma attributable to the drug [1].

Fertility is another consideration. Mesterolone was historically marketed as a treatment for oligospermia in some countries, but the evidence is contradictory. A Cochrane review by Attia et al. (2009) analyzed 7 randomized trials of mesterolone for male subfertility (total N=422) and concluded: "There is no evidence that mesterolone improves the pregnancy rate in couples with male factor subfertility" [15]. The review noted that semen parameters showed inconsistent responses across trials.

Who Might Consider Mesterolone (and Who Should Not)

In countries where mesterolone is legally prescribed, it occupies a narrow clinical niche. Candidates typically include men already on injectable TRT who have persistent estrogen-related side effects despite aromatase inhibitor therapy, or men in regions where injectable testosterone is difficult to access. Even in those cases, the evidence base is thin.

Men who should avoid mesterolone: anyone with a history of prostate cancer or clinically significant benign prostatic hyperplasia, given mesterolone's direct DHT-receptor agonism. The American Urological Association's 2018 guideline on testosterone therapy states that "patients with metastatic prostate cancer should not receive testosterone therapy" and recommends PSA monitoring in all men receiving androgen therapy [16]. This caution applies equally to mesterolone.

US-based men seeking TRT have better-studied options. Testosterone cypionate, testosterone enanthate, transdermal testosterone (1% gel or 1.62% gel), intranasal testosterone (Natesto), and subcutaneous pellets all carry FDA approval, established dosing guidelines, and decades of safety surveillance.

How to Choose the Right TRT Formulation

Selecting among FDA-approved testosterone formulations depends on three practical factors: injection tolerance, dose-adjustment flexibility, and insurance coverage.

For men comfortable with self-injection, testosterone cypionate 100 to 200 mg weekly (or split into twice-weekly subcutaneous doses of 50 to 100 mg) offers the best combination of cost, convenience, and pharmacokinetic stability. Generic cypionate costs $30 to $60 per 10 mL vial (200 mg/mL) without insurance, covering 10 to 20 weeks of therapy [5].

For men who want to avoid needles entirely, transdermal testosterone gel (AndroGel, Testim, or generic 1%) provides daily dosing with steady-state levels reached within 2 to 4 weeks. The main limitation: gel requires careful skin-to-skin transfer precautions, particularly around women and children.

Testosterone pellets suit men who prioritize convenience and have budgets accommodating the every-4-to-6-month procedure. The per-year cost typically ranges from $1,200 to $2,400, depending on the number of pellets and provider fees [11].

Regardless of formulation, the 2018 Endocrine Society guideline recommends baseline and follow-up monitoring of total testosterone, hematocrit, PSA, and lipid panel at 3, 6, and 12 months after initiating therapy, then annually [4].